Literature DB >> 24531750

T lymphocytes restrain spontaneous metastases in permanent dormancy.

Irene Romero1, Cristina Garrido, Ignacio Algarra, Antonia Collado, Federico Garrido, Angel M Garcia-Lora.   

Abstract

Tumor dormancy is a clinical phenomenon related to immune equilibrium during cancer immunoediting. The mechanisms involved in dormant metastases are poorly understood due to the lack of preclinical models. Here, we present a nontransgenic mouse model in which spontaneous metastases remain in permanent immunomediated dormancy with no additional antitumor treatment. After the injection of a GR9-B11 mouse fibrosarcoma clone into syngeneic BALB/c mice, all animals remained free of spontaneous metastases at the experimental endpoints (3-8 months) but also as long as 24 months after tumor cell injection. Strikingly, when tumor-bearing mice were immunodepleted of T lymphocytes or asialo GM1-positive cells, the restraint on dormant disseminated metastatic cells was relieved and lung metastases progressed. Immunostimulation was documented at both local and systemic levels, with results supporting the evidence that the immune system was able to restrain spontaneous metastases in permanent dormancy. Notably, the GR9-B11 tumor clone did not express MHC class I molecules on the cell surface, yet all metastases in immunodepleted mice were MHC class I-positive. This model system may be valuable for more in-depth analyses of metastatic dormancy, offering new opportunities for immunotherapeutic management of metastatic disease. ©2014 AACR.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24531750     DOI: 10.1158/0008-5472.CAN-13-2084

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  23 in total

Review 1.  Tumor Dormancy and Relapse: From a Natural Byproduct of Evolution to a Disease State.

Authors:  Masoud H Manjili
Journal:  Cancer Res       Date:  2017-05-15       Impact factor: 12.701

Review 2.  Innate and acquired immune surveillance in the postdissemination phase of metastasis.

Authors:  Hugo Gonzalez; Isabella Robles; Zena Werb
Journal:  FEBS J       Date:  2017-11-24       Impact factor: 5.542

Review 3.  MHC heterogeneity and response of metastases to immunotherapy.

Authors:  Ignacio Algarra; Federico Garrido; Angel M Garcia-Lora
Journal:  Cancer Metastasis Rev       Date:  2021-04-15       Impact factor: 9.264

Review 4.  Immune Regulation of the Metastatic Process: Implications for Therapy.

Authors:  A de Mingo Pulido; B Ruffell
Journal:  Adv Cancer Res       Date:  2016-06-17       Impact factor: 6.242

Review 5.  Multifaceted functions of chronic inflammation in regulating tumor dormancy and relapse.

Authors:  Saeed H Manjili; Madison Isbell; Negar Ghochaghi; Tyler Perkinson; Masoud H Manjili
Journal:  Semin Cancer Biol       Date:  2021-03-27       Impact factor: 15.707

Review 6.  Cancer Dormancy: A Regulatory Role for Endogenous Immunity in Establishing and Maintaining the Tumor Dormant State.

Authors:  Constantin N Baxevanis; Sonia A Perez
Journal:  Vaccines (Basel)       Date:  2015-07-30

7.  MHC Intratumoral Heterogeneity May Predict Cancer Progression and Response to Immunotherapy.

Authors:  Irene Romero; Cristina Garrido; Ignacio Algarra; Virginia Chamorro; Antonia Collado; Federico Garrido; Angel M Garcia-Lora
Journal:  Front Immunol       Date:  2018-01-29       Impact factor: 7.561

Review 8.  The Immune Microenvironment and Cancer Metastasis.

Authors:  Asmaa El-Kenawi; Kay Hänggi; Brian Ruffell
Journal:  Cold Spring Harb Perspect Med       Date:  2020-04-01       Impact factor: 6.915

9.  A novel preclinical murine model of immune-mediated metastatic dormancy.

Authors:  Irene Romero; Federico Garrido; Angel M Garcia-Lora
Journal:  Oncoimmunology       Date:  2014-06-25       Impact factor: 8.110

Review 10.  The urgent need to recover MHC class I in cancers for effective immunotherapy.

Authors:  Federico Garrido; Natalia Aptsiauri; Elien M Doorduijn; Angel M Garcia Lora; Thorbald van Hall
Journal:  Curr Opin Immunol       Date:  2016-01-18       Impact factor: 7.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.